questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Effets physiologiques des médicaments
Facteurs immunologiques
Immunosuppresseurs
Immunosuppresseurs : Questions médicales fréquentes
Termes MeSH sélectionnés :
Multicenter Studies as Topic
Diagnostic
5
Maladies auto-immunes
Tests sanguins
Rejet d'organe
Tests de compatibilité
Fatigue
Douleurs articulaires
Symptômes
5
Effets secondaires
Infections
Allergies
Éruptions cutanées
Réaction indésirable
Saignements
Prévention
5
Prévention des infections
Vaccination
Sécurité alimentaire
Infections alimentaires
Gestion du stress
Soutien psychologique
Suivi médical
Fonction rénale
Interactions médicamenteuses
Consultation médicale
Traitements
5
Corticostéroïdes
Inhibiteurs de calcineurine
Voie orale
Administration intraveineuse
Durée du traitement
Maladies chroniques
Thérapies biologiques
Médicaments anti-inflammatoires
Complications
5
Complications
Infections graves
Risque de cancer
Immunosuppression
Gestion des complications
Suivi médical
Facteurs de risque
5
Antécédents médicaux
Maladies auto-immunes
Mode de vie
Réponse au traitement
Antibiotiques
Interactions médicamenteuses
Antécédents familiaux
Maladies auto-immunes
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Immunosuppresseurs : Questions médicales les plus fréquentes",
"headline": "Immunosuppresseurs : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Immunosuppresseurs : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-27",
"dateModified": "2025-04-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Immunosuppresseurs"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Facteurs immunologiques",
"url": "https://questionsmedicales.fr/mesh/D007155",
"about": {
"@type": "MedicalCondition",
"name": "Facteurs immunologiques",
"code": {
"@type": "MedicalCode",
"code": "D007155",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du complément",
"alternateName": "Complement Inactivating Agents",
"url": "https://questionsmedicales.fr/mesh/D051056",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du complément",
"code": {
"@type": "MedicalCode",
"code": "D051056",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477.656.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Antagonistes du récepteur B2 de la bradykinine",
"alternateName": "Bradykinin B2 Receptor Antagonists",
"url": "https://questionsmedicales.fr/mesh/D065094",
"about": {
"@type": "MedicalCondition",
"name": "Antagonistes du récepteur B2 de la bradykinine",
"code": {
"@type": "MedicalCode",
"code": "D065094",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477.656.500.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des interleukines",
"alternateName": "Interleukin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000088902",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des interleukines",
"code": {
"@type": "MedicalCode",
"code": "D000088902",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477.656.563"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'interleukine-6",
"alternateName": "Interleukin-6 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000093242",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'interleukine-6",
"code": {
"@type": "MedicalCode",
"code": "D000093242",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477.656.594"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Modulateurs des récepteurs de la sphingosine 1 phosphate",
"alternateName": "Sphingosine 1 Phosphate Receptor Modulators",
"url": "https://questionsmedicales.fr/mesh/D000081243",
"about": {
"@type": "MedicalCondition",
"name": "Modulateurs des récepteurs de la sphingosine 1 phosphate",
"code": {
"@type": "MedicalCode",
"code": "D000081243",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477.656.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Immunosuppresseurs",
"alternateName": "Immunosuppressive Agents",
"code": {
"@type": "MedicalCode",
"code": "D007166",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Koichi Kamei",
"url": "https://questionsmedicales.fr/author/Koichi%20Kamei",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan. kamei-k@ncchd.go.jp."
}
},
{
"@type": "Person",
"name": "Masao Ogura",
"url": "https://questionsmedicales.fr/author/Masao%20Ogura",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Kensuke Shoji",
"url": "https://questionsmedicales.fr/author/Kensuke%20Shoji",
"affiliation": {
"@type": "Organization",
"name": "Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Shuichi Ito",
"url": "https://questionsmedicales.fr/author/Shuichi%20Ito",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, Yokohama City University Hospital, Kanagawa, Japan."
}
},
{
"@type": "Person",
"name": "Dorota Iwaszkiewicz-Grześ",
"url": "https://questionsmedicales.fr/author/Dorota%20Iwaszkiewicz-Grze%C5%9B",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Immunology, Faculty of Medicine, Medical University of Gdansk, ul. Dębinki 7, 80-210 Gdańsk, Poland."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial.",
"datePublished": "2022-07-08",
"url": "https://questionsmedicales.fr/article/35804404",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-022-06365-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Access to rehabilitation after stroke in Brazil (AReA study): multicenter study protocol.",
"datePublished": "2022-12-19",
"url": "https://questionsmedicales.fr/article/36535291",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/s-0042-1758558"
}
},
{
"@type": "ScholarlyArticle",
"name": "Surgical Outcomes of Primary Dermatofibrosarcoma Protuberans: A Retrospective, Multicenter Study.",
"datePublished": "2022-08-06",
"url": "https://questionsmedicales.fr/article/35933538",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-022-12351-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Study Protocol of a Prospective Multicenter Observational Study Evaluating Acute Lower Limb Ischemia.",
"datePublished": "2022-11-05",
"url": "https://questionsmedicales.fr/article/36347128",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jss.2022.09.023"
}
},
{
"@type": "ScholarlyArticle",
"name": "Study protocol of Branch Atheromatous Disease-related stroke (BAD-study): a multicenter prospective cohort study.",
"datePublished": "2022-12-09",
"url": "https://questionsmedicales.fr/article/36494618",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12883-022-02976-9"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Effets physiologiques des médicaments",
"item": "https://questionsmedicales.fr/mesh/D045505"
},
{
"@type": "ListItem",
"position": 5,
"name": "Facteurs immunologiques",
"item": "https://questionsmedicales.fr/mesh/D007155"
},
{
"@type": "ListItem",
"position": 6,
"name": "Immunosuppresseurs",
"item": "https://questionsmedicales.fr/mesh/D007166"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Immunosuppresseurs - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Immunosuppresseurs",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Immunosuppresseurs",
"description": "Comment diagnostiquer une nécessité d'immunosuppresseurs ?\nQuels tests sont utilisés pour évaluer l'immunité ?\nQuels signes indiquent un besoin d'immunosuppresseurs ?\nComment évaluer le risque de rejet d'organe ?\nQuels symptômes nécessitent un traitement immunosuppresseur ?",
"url": "https://questionsmedicales.fr/mesh/D007166?mesh_terms=Multicenter+Studies+as+Topic#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Immunosuppresseurs",
"description": "Quels sont les effets secondaires des immunosuppresseurs ?\nComment reconnaître une infection due à l'immunosuppression ?\nQuels symptômes d'allergie peuvent survenir ?\nLes immunosuppresseurs causent-ils des troubles digestifs ?\nQuels signes indiquent une réaction indésirable ?",
"url": "https://questionsmedicales.fr/mesh/D007166?mesh_terms=Multicenter+Studies+as+Topic#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Immunosuppresseurs",
"description": "Comment prévenir les infections sous immunosuppression ?\nQuelles précautions alimentaires prendre ?\nComment gérer le stress pendant le traitement ?\nQuels examens de suivi sont nécessaires ?\nComment éviter les interactions médicamenteuses ?",
"url": "https://questionsmedicales.fr/mesh/D007166?mesh_terms=Multicenter+Studies+as+Topic#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Immunosuppresseurs",
"description": "Quels types d'immunosuppresseurs existent ?\nComment sont administrés les immunosuppresseurs ?\nQuelle est la durée du traitement immunosuppresseur ?\nComment ajuster la posologie des immunosuppresseurs ?\nQuels sont les traitements alternatifs aux immunosuppresseurs ?",
"url": "https://questionsmedicales.fr/mesh/D007166?mesh_terms=Multicenter+Studies+as+Topic#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Immunosuppresseurs",
"description": "Quelles sont les complications possibles des immunosuppresseurs ?\nComment reconnaître une infection grave ?\nLes immunosuppresseurs augmentent-ils le risque de cancer ?\nQuels troubles métaboliques peuvent survenir ?\nComment gérer les complications liées aux immunosuppresseurs ?",
"url": "https://questionsmedicales.fr/mesh/D007166?mesh_terms=Multicenter+Studies+as+Topic#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Immunosuppresseurs",
"description": "Quels facteurs augmentent le besoin d'immunosuppresseurs ?\nComment l'âge influence-t-il le traitement ?\nLe mode de vie affecte-t-il l'immunosuppression ?\nQuels médicaments augmentent le risque d'interactions ?\nLes antécédents familiaux influencent-ils le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D007166?mesh_terms=Multicenter+Studies+as+Topic#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une nécessité d'immunosuppresseurs ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation clinique et des tests sanguins pour évaluer l'auto-immunité."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'immunité ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme le dosage des anticorps et des lymphocytes T sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent un besoin d'immunosuppresseurs ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des inflammations chroniques ou des éruptions cutanées peuvent indiquer ce besoin."
}
},
{
"@type": "Question",
"name": "Comment évaluer le risque de rejet d'organe ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par des tests de compatibilité et des marqueurs immunologiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent un traitement immunosuppresseur ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue extrême ou des douleurs articulaires peuvent nécessiter un traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des immunosuppresseurs ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent infections, fatigue, et troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une infection due à l'immunosuppression ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme fièvre, frissons ou douleurs inhabituelles peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'allergie peuvent survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, démangeaisons ou gonflements peuvent être des signes d'allergie."
}
},
{
"@type": "Question",
"name": "Les immunosuppresseurs causent-ils des troubles digestifs ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des nausées, vomissements ou diarrhées peuvent survenir avec certains immunosuppresseurs."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une réaction indésirable ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des douleurs abdominales ou des saignements peuvent signaler une réaction."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections sous immunosuppression ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est essentiel de se faire vacciner et d'éviter les contacts avec des personnes malades."
}
},
{
"@type": "Question",
"name": "Quelles précautions alimentaires prendre ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez les aliments crus et assurez-vous que les aliments sont bien cuits pour prévenir les infections."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress pendant le traitement ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques de relaxation et un soutien psychologique peuvent aider à gérer le stress."
}
},
{
"@type": "Question",
"name": "Quels examens de suivi sont nécessaires ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers de la fonction rénale et des tests sanguins sont nécessaires pour le suivi."
}
},
{
"@type": "Question",
"name": "Comment éviter les interactions médicamenteuses ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Informez toujours votre médecin de tous les médicaments que vous prenez pour éviter les interactions."
}
},
{
"@type": "Question",
"name": "Quels types d'immunosuppresseurs existent ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux types incluent les corticostéroïdes, les inhibiteurs de calcineurine et les agents biologiques."
}
},
{
"@type": "Question",
"name": "Comment sont administrés les immunosuppresseurs ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale, intraveineuse ou sous-cutanée selon le médicament."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement immunosuppresseur ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée varie selon la maladie, allant de quelques mois à plusieurs années."
}
},
{
"@type": "Question",
"name": "Comment ajuster la posologie des immunosuppresseurs ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La posologie est ajustée en fonction des résultats des tests sanguins et de la réponse clinique."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements alternatifs aux immunosuppresseurs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements alternatifs incluent des thérapies biologiques et des médicaments anti-inflammatoires."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des immunosuppresseurs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections graves, des cancers et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une infection grave ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme une forte fièvre, des frissons ou une confusion peuvent indiquer une infection grave."
}
},
{
"@type": "Question",
"name": "Les immunosuppresseurs augmentent-ils le risque de cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'utilisation prolongée d'immunosuppresseurs peut augmenter le risque de certains cancers."
}
},
{
"@type": "Question",
"name": "Quels troubles métaboliques peuvent survenir ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles comme le diabète ou l'hypertension peuvent survenir avec certains immunosuppresseurs."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux immunosuppresseurs ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi régulier, des ajustements de traitement et une surveillance des symptômes."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le besoin d'immunosuppresseurs ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de maladies auto-immunes ou de transplantation augmentent ce besoin."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le traitement ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées peuvent avoir un risque accru d'effets secondaires et nécessiter des ajustements."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il l'immunosuppression ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire les risques d'infections et améliorer la réponse au traitement."
}
},
{
"@type": "Question",
"name": "Quels médicaments augmentent le risque d'interactions ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains antibiotiques et antifongiques peuvent interagir avec les immunosuppresseurs."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le traitement ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies auto-immunes peuvent augmenter le risque de développer des maladies similaires."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 22/04/2025
Contenu vérifié selon les dernières recommandations médicales
5 publications dans cette catégorie
Affiliations :
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan. kamei-k@ncchd.go.jp.
Publications dans "Immunosuppresseurs" :
4 publications dans cette catégorie
Affiliations :
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
4 publications dans cette catégorie
Affiliations :
Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Yokohama City University Hospital, Kanagawa, Japan.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Department of Medical Immunology, Faculty of Medicine, Medical University of Gdansk, ul. Dębinki 7, 80-210 Gdańsk, Poland.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Department of Organic Chemistry, Faculty of Chemistry, Gdańsk University of Technology, G. Narutowicza 11/12, 80-233 Gdańsk, Poland.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Postgraduate Program in Pharmaceutical Sciences, Health Sciences Centre, Federal University of Santa Maria (UFSM), Santa Maria, RS, Brazil. Electronic address: luana.farma@hotmail.com.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Postgraduate Program in Pharmaceutical Sciences, Health Sciences Centre, Federal University of Santa Maria (UFSM), Santa Maria, RS, Brazil.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Department of Preventive Veterinary Medicine, Veterinary School, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Postgraduate Program in Pharmacology, Health Sciences Centre, Federal University of Santa Maria (UFSM), Santa Maria, RS, Brazil.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Postgraduate Program in Pharmaceutical Sciences, Health Sciences Centre, Federal University of Santa Maria (UFSM), Santa Maria, RS, Brazil.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Gastroenterology, University of California, San Diego, CA.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Immunology, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations presenting as clusters of cysts filled with lymph fluid or blood. Even small well-limited lesions can be ...
This is a randomized, multicentric study using an individually randomized stepped-wedge design over 24 weeks to evaluate topical application of a 1 mg/mL sirolimus solution once daily, on LMLM, versus...
Given the disappointing state of current treatment options in LMLMs, topical sirolimus could become firstline therapy in treating LMLMs if its efficacy and safety were to be demonstrated....
ClinicalTrials.gov NCT04128722 . Registered on 24 September 2019. EudraCT: EUCTR2019-001530-33-FR Sponsor (University Hospital Center of Tours - CHRU Tours): DR190041-TOPGUN French regulatory authorit...
Most of the Brazilian population relies on public healthcare and stroke is a major cause of disability in this country of continental dimensions. There is limited information about access to rehabilit...
To provide comprehensive information about Access to Rehabilitation After discharge from public hospitals in Brazil (AReA study), up to 6 months after stroke....
The present study intends to collect information from 17 public health centers in 16 Brazilian cities in the 5 macroregions of the country. Each center will include 36 participants (...
The study is ongoing. Recruitment started on January 31...
The AReA study will fill a gap in knowledge about access to stroke rehabilitation in the public health system in different Brazilian regions....
Dermatofibrosarcoma protuberans (DFSP) is a locally aggressive tumor with a low rate of metastatic disease. Previous series have shown a superiority of Mohs micrographic surgery (MMS) compared with wi...
The purpose of the current study was to examine the outcome of surgical treatment of primary DFSP of the trunk and extremities....
We reviewed 236 patients (115 females, 121 males, mean age 41 ± 15 years) undergoing MMS (n = 81, 34%) or WLE (n = 155, 66%) to treat a primary DFSP. Mean tumor size and follow-up was 4 ± 2 cm and 7 y...
There was no difference (p > 0.05) in patient age, sex, tumor size, negative margin excision, or history of a previous inadvertent excision between patients who underwent WLE and those undergoing MMS....
There was no difference in oncologic outcome comparing MMS with WLE for DFSP outside the head and neck. The goal of treatment for DFSP is to achieve a negative margin, regardless of surgical treatment...
Acute lower limb ischemia (ALI) is a limb- and potentially life-threatening condition which requires urgent evaluation and treatment. Contemporary data on optimal therapy and prognosis of ALI are lack...
The proposed study is a prospective, international, multicenter, observational study on ALI (PROMOTE-ALI) (ClinicalTrials.gov - NCT05138679). Patients with ALI (Rutherford classification grade I -III)...
ALI remains a challenging condition and due to the heterogeneous etiology, clinical presentation and treatment strategies, a large multicenter study on this topic is needed to gain contemporary data o...
As a meaningful subtype of ischemic stroke in Asians, Branch atheromatous disease (BAD)-related stroke is associated with high early neurological deterioration (END) and disability, but is understudie...
BAD-study is a nationwide, multicenter, consecutive, prospective, observational cohort study enrolling patients aged 18-80 years with BAD-related stroke within 72 h after symptom onset. Initial clinic...
BAD-study can provide demographic, clinical, radiological, and prognostic characteristics of BAD-related stroke, and thereby potentially figure out the vascular mechanism of early neurological deterio...
Narrowband ultraviolet B (NB-UVB) phototherapy is commonly prescribed for patients with moderate-to-severe atopic eczema (AE). The efficacy of NB-UVB, however, has not yet properly been established, a...
A pragmatic, multicenter, PROBE trial will be performed with 1:1 randomization of 316 adult patients with moderate-to-severe AE who have inadequate disease control with topical therapy and who are eli...
The UPDATE trial aims to provide high-quality evidence regarding the (cost-)effectiveness and safety of NB-UVB phototherapy in moderate-to-severe AE patients. Challenges that are addressed in the prot...
ClinicalTrials.gov NCT05704205. Registered on December 8, 2022....
Epidemiological data on cerebral venous thrombosis in China are still lacking at present on the aspects of incidence, recurrence, risk factors, and so on. Herein, we aimed to fill the gap, based on th...
Rectal cancer is a common cancer worldwide. Surgery for rectal cancer with low anterior resection often includes the formation of a temporary protective loop ileostomy. The temporary ostomy is later r...
The present multicenter, double-blinded, randomized, controlled study will compare standard suture closure of the abdominal wall in loop ileostomy reversal with retromuscular synthetic mesh at the sto...
This double-blinded randomized controlled superiority study will compare retromuscular synthetic mesh during the closure of loop ileostomy to standard care. If this study can show a lower frequency of...
ClinicalTrials.gov NCT03720262. Registered on October 25, 2018....
Multicenter contemporary data describing short-term outcomes after initial interventions of neonates with pulmonary atresia with intact ventricular septum (PA-IVS) are limited. This multicenter study ...
Neonates with PA-IVS who underwent surgical or catheter intervention between 2009 and 2019 in 19 centers were reviewed. Risk factors for MACE, defined as cardiopulmonary resuscitation, mechanical circ...
We reviewed 279 neonates: 79 (28%) underwent right ventricular decompression, 151 (54%) underwent systemic-to-pulmonary shunt or ductal stent placement only, 36 (13%) underwent right ventricular decom...
In a multicenter cohort, 1 in 5 neonates with PA-IVS experienced MACE after their initial intervention. Patients with 2 major coronary artery stenoses or lower weight at the time of the initial proced...
Cases of Toxoplasma reactivation or more severe primary infection have been reported in patients receiving immunosuppressive (IS) treatment for autoimmune diseases (AID). The purpose of this study was...
A multicenter descriptive study was conducted using data from the French National Reference Center for Toxoplasmosis (NRCT) that received DNA extracts or strains isolated from patients, associated wit...
61 cases were collected: 25 retrieved by the NRCT and by a call for observations and 36 from a literature review. Half of the cases were attributed to reactivation (50.9%), and most of cases (49.2%) w...
Although this remains a rare condition, clinicians should be aware for the management of patients and for the choice of IS treatment....